AU2001292612A1 - Efficient process for the preparation of a factor XA inhibitor - Google Patents

Efficient process for the preparation of a factor XA inhibitor

Info

Publication number
AU2001292612A1
AU2001292612A1 AU2001292612A AU9261201A AU2001292612A1 AU 2001292612 A1 AU2001292612 A1 AU 2001292612A1 AU 2001292612 A AU2001292612 A AU 2001292612A AU 9261201 A AU9261201 A AU 9261201A AU 2001292612 A1 AU2001292612 A1 AU 2001292612A1
Authority
AU
Australia
Prior art keywords
compound
formula
process according
solvent
contacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001292612A
Other languages
English (en)
Inventor
Luigi Anzalone
Fuqiang Jin
Hui-Yin Li
David J. Meloni
Thomas E. Smyser
Jung-Hui Sun
Christopher A. Teleh
Jiacheng Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
EI Du Pont de Nemours and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EI Du Pont de Nemours and Co filed Critical EI Du Pont de Nemours and Co
Publication of AU2001292612A1 publication Critical patent/AU2001292612A1/en
Assigned to BRISTOL-MYERS SQUIBB PHARMA COMPANY reassignment BRISTOL-MYERS SQUIBB PHARMA COMPANY Amend patent request/document other than specification (104) Assignors: DUPONT PHARMACEUTICALS COMPANY
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2001292612A 2000-09-22 2001-09-12 Efficient process for the preparation of a factor XA inhibitor Abandoned AU2001292612A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23462200P 2000-09-22 2000-09-22
US60/234,622 2000-09-22
PCT/US2001/028406 WO2002024690A2 (en) 2000-09-22 2001-09-12 Efficient process for the preparation of a factor xa inhibitor

Publications (1)

Publication Number Publication Date
AU2001292612A1 true AU2001292612A1 (en) 2002-04-02

Family

ID=22882119

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001292612A Abandoned AU2001292612A1 (en) 2000-09-22 2001-09-12 Efficient process for the preparation of a factor XA inhibitor

Country Status (23)

Country Link
US (3) US6667332B2 (xx)
EP (1) EP1366045A2 (xx)
JP (1) JP2004529853A (xx)
KR (1) KR20040043089A (xx)
CN (1) CN1610679A (xx)
AU (1) AU2001292612A1 (xx)
BG (1) BG107813A (xx)
BR (1) BR0114102A (xx)
CA (1) CA2424576A1 (xx)
CZ (1) CZ2003835A3 (xx)
EE (1) EE200300116A (xx)
HR (1) HRP20030316A2 (xx)
HU (1) HUP0500133A2 (xx)
IL (1) IL155043A0 (xx)
IS (1) IS6754A (xx)
MX (1) MXPA03002493A (xx)
NO (1) NO20031308L (xx)
PL (1) PL366027A1 (xx)
RU (1) RU2003111464A (xx)
SK (1) SK4892003A3 (xx)
TW (1) TW593314B (xx)
WO (1) WO2002024690A2 (xx)
ZA (1) ZA200302971B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
IL153378A0 (en) * 2000-07-18 2003-07-06 Bone Care Internat Inc STABILIZED 1alpha-HYDROXY VITAMIN D
TW200302225A (en) * 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
AU2003270861A1 (en) * 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
WO2004041710A1 (ja) * 2002-11-06 2004-05-21 Matsushita Electric Industrial Co., Ltd. 変位検出機能を備えたマイクロアクチュエータ、および当該マイクロアクチュエータを備えた可変形ミラー
US7429581B2 (en) * 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US20050059719A1 (en) * 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
MX2016011468A (es) 2014-03-07 2017-01-23 Biocryst Pharm Inc Inhibidores de calicreína plasmática humana.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
ZA985247B (en) * 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors

Also Published As

Publication number Publication date
TW593314B (en) 2004-06-21
CA2424576A1 (en) 2002-03-28
BG107813A (bg) 2004-01-30
ZA200302971B (en) 2005-05-09
NO20031308L (no) 2003-05-07
CN1610679A (zh) 2005-04-27
IS6754A (is) 2003-03-21
US20020061917A1 (en) 2002-05-23
IL155043A0 (en) 2003-10-31
WO2002024690A3 (en) 2003-09-25
NO20031308D0 (no) 2003-03-21
RU2003111464A (ru) 2004-10-27
BR0114102A (pt) 2005-04-19
MXPA03002493A (es) 2004-09-10
EP1366045A2 (en) 2003-12-03
HRP20030316A2 (en) 2005-02-28
EE200300116A (et) 2005-04-15
PL366027A1 (en) 2005-01-24
US20030212117A1 (en) 2003-11-13
WO2002024690A8 (en) 2002-08-08
US6747158B2 (en) 2004-06-08
CZ2003835A3 (cs) 2003-12-17
SK4892003A3 (en) 2004-04-06
US6667332B2 (en) 2003-12-23
US20040198787A1 (en) 2004-10-07
KR20040043089A (ko) 2004-05-22
JP2004529853A (ja) 2004-09-30
HUP0500133A2 (hu) 2005-04-28
WO2002024690A2 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
US6369227B1 (en) Thrombin or factor Xa inhibitors
EP1175419B1 (en) Aryl sulfonyls as factor xa inhibitors
EP1196412B1 (en) Nitrogen containing heterobicycles as factor xa inhibitors
US20040214808A1 (en) Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
EP1226123A1 (en) Cyano compounds as factor xa inhibitors
US6750225B2 (en) 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors
US6667332B2 (en) Efficient process for the preparation of a factor Xa inhibitor
US20030144287A1 (en) Novel N-[4- (1H-imidazol-1-yl) -2-fluorophenyl ] -3- (trifluoromethyl) -1H-pyrazole-5-carboxamides as factor Xa inhibitors
US20020022614A1 (en) Thrombin or factor Xa inhibitors
US6706730B2 (en) 1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-ones as factor Xa inhibitors
US6407256B1 (en) Cyano-pyrrole, cyano-imidazole, cyano-pyrazole, and cyano-triazole compounds as factor Xa inhibitors

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application